№ files_lp_4_process_3_096079
File format: docx
Character count: 4985
File size: 108 KB
This document outlines the specifications for providing endometrial biopsy services to patients within the Doncaster area, including guidelines for practitioners and protocols for patient management.
Year:
2017-2018
Region / city:
Doncaster
Subject:
Gynaecology, Endometrial Biopsy
Document Type:
Service Specification
Organization:
NHS Doncaster CCG
Author:
Not specified
Target Audience:
Healthcare providers, GPs
Effective Period:
1st April 2017 to 31st March 2018
Approval Date:
Not specified
Date of Last Review:
Annual
Changes Date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2024
Region / city:
Global
Theme:
Oncology, Endometrial Cancer, Pharmaceutical Submissions
Document Type:
Medical Submission
Organization / Institution:
AstraZeneca Pty Ltd
Author:
AstraZeneca Pty Ltd
Target Audience:
Medical professionals, regulatory bodies, pharmaceutical companies
Period of validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2022
Country:
Australia
Therapeutic area:
Oncology
Disease:
Endometrial cancer
Biomarker status:
Mismatch repair deficient (dMMR)
Medicine name:
Dostarlimab
Brand name:
Jemperli
Dosage form:
Solution concentrate for intravenous infusion
Sponsor:
GlaxoSmithKline Australia Pty Ltd
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission type:
Standard Re-entry submission
Requested listing:
Section 100
Comparator treatments:
Standard of care chemotherapy; pembrolizumab plus lenvatinib; pembrolizumab monotherapy
Clinical trial referenced:
GARNET
Approval status:
Provisional approval
Indication:
Recurrent or advanced endometrial cancer after platinum-containing regimen
Decision context:
PBS listing consideration
Period covered:
Up to November 2022
Year:
n.d.
Region / city:
n.d.
Topic:
Cancer research
Document type:
Supplementary table
Organization / institution:
n.d.
Author:
n.d.
Target audience:
Researchers, medical professionals
Effective period:
n.d.
Approval date:
n.d.
Amendment date:
n.d.
Year:
2019
Month:
January
Organisation:
British Gynaecological Cancer Society (BGCS)
Region:
United Kingdom
Field:
Gynaecological Oncology
Topic:
Sentinel Lymph Node Technique in Vulval, Cervical and Endometrial Cancer
Document Type:
Consensus Statement
Authors:
Christina Fotopoulou; Thomas Ind; Peter Baldwin; Robin Crawford; Omer Devaja; Stephen Dobbs; Jonathan Frost; Ketan Gajjar; Raji Ganesan; Sonali Kaushik; Jo Morrison; Marielle Nobbenhuis; Nithya Ratnavelu; Phil Rolland; Naveena Singh; Alexandra Taylor; Sudha Sundar; Andy Nordin
Participating Body:
BGCS officers and expert members of the UK gynaecological oncological community
Methodology:
Delphi process with two rounds and 80% consensus threshold
Scope:
Applicability, oncologic safety and surgical safety of sentinel lymph node algorithms
Cancers Addressed:
Vulval cancer; Cervical cancer; Endometrial cancer
Guidelines Considered:
European Society of Gynaecological Oncologists (ESGO)
Implementation Context:
UK gynaecological cancer centres
Clinical Focus:
Surgical staging; SLN mapping; Lymphadenectomy; Histological ultra-staging; Training and audit requirements
Year:
2023
Region / City:
N/A
Subject:
Endometrial Cancer Surgery Accreditation
Document Type:
Application Form
Organization / Institution:
ESGO
Author:
N/A
Target Audience:
Medical centers, healthcare professionals
Period of validity:
N/A
Approval Date:
N/A
Date of changes:
N/A
Year:
2026
Region / City:
Not specified
Subject:
Molecular and cellular analysis of endometrial cancer
Document Type:
Supplementary figures
Institution:
Not specified
Authors:
Not specified
Target Audience:
Researchers in oncology and molecular biology
Study Period:
Not specified
Data Sources:
Human endometrial cancer patients, cancer cell lines, mouse endometrial tissues, TCGA database
Methods:
Immunohistochemistry, immunofluorescence, ChIP-seq, RT-qPCR, AFM
Measured Parameters:
Gene expression, cell migration, apoptosis, cytoskeleton content, adhesion force
Statistical Significance Indicators:
* P<0.05, ** P<0.01, *** P<0.005, **** P<0.001
Year:
2021
Region / City:
International
Topic:
Soft tissue sarcoma histopathology
Document Type:
Guide
Organization / Institution:
International Collaboration on Cancer Reporting (ICCR)
Author:
Not specified
Target Audience:
Pathologists, oncologists, medical professionals
Effective Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Version:
1.2.0.0
Protocol posting date:
March 2023
Document type:
Clinical pathology protocol
Medical field:
Breast pathology, oncology
Procedures covered:
Needle biopsy, fine needle aspiration, other biopsy procedures
Tumor types included:
Invasive breast carcinoma of any type, with or without ductal carcinoma in situ
Tumor types excluded:
Ductal carcinoma in situ without invasion, Paget disease without invasion, phyllodes tumor, lymphoma, sarcoma
Authors:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Organization:
College of American Pathologists
Accreditation status:
Recommended for clinical care, not required for accreditation
Intended use:
Reporting of biopsy specimens
Updates:
Optional reporting of largest invasive focus; revised lymphatic and/or vascular invasion terminology
Note:
Year
Theme:
Neuropathology, Biopsy, Medical Guidelines
Document Type:
Guidelines
Organization / Institution:
Southmead Hospital
Target Audience:
Medical professionals, Neuropathologists
Context:
Guidelines for handling and sending nerve biopsy specimens to the Neuropathology Department for analysis and further processing.
Note:
Year
Subject:
Neuropathology, Prion Diseases
Document Type:
Procedure
Organization / Institution:
National Prion Disease Pathology Surveillance Center
Author:
Chad Patete for Dr. Gambetti
Target Audience:
Neuropathologists, Medical Staff
Version:
4.2.0.0
Protocol Posting Date:
June 2024
Year:
2024
Region / city:
Not specified
Topic:
Bone tumor biopsy protocols
Document type:
Protocol
Organization / institution:
Not specified
Author:
Paari Murugan, MD, FCAP; Julie C. Fanburg-Smith, MD, FCAP; Andrew Horvai, MD, PhD; Fernanda Amary, MD, PhD; Meera Hameed, MD, FCAP; Michael J. Klein, MD
Target audience:
Clinicians and pathologists involved in biopsy procedures for bone tumors
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2017
Region / City:
Miami, Florida
Subject:
Procurement of Medical Equipment
Document Type:
Combined Synopsis/Solicitation
Agency:
Department of Veterans Affairs
Author:
Department of Veterans Affairs
Target Audience:
Service Disabled/Veteran Owned Small Businesses
Period of Effectiveness:
From January 19, 2017
Approval Date:
January 19, 2017
Modification Date:
N/A
Note:
Year
Topic:
Medical Procedure
Document Type:
Educational Material and Consent Form
Target Audience:
Patients undergoing vulvar biopsy
Contextual description:
Document providing detailed information and consent form for patients undergoing vulvar biopsy, including risks, procedure details, and alternatives.
Subject:
Lung cancer diagnosis and procedure coding
Diagnosis codes:
ICD-9 162.0, 162.2, 162.3, 162.4, 162.5, 162.8, 162.9; ICD-10 C33, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92
Procedure codes:
CPT, ICD-9 Procedure, ICD-10 Procedure
Clinical focus:
Biopsy procedures, CT scans, treatments, and post-procedural complications
Complication types:
Pneumothorax, prolonged air leak, hemorrhage, intubation/mechanical ventilation, mediastinitis, pneumonia, empyema, abscess of lung
Setting:
Inpatient and outpatient hospital care
Cost attribution rule:
Inpatient biopsies after day 2 costed at outpatient rate
Purpose:
Patient selection and identification of post-procedural complications and treatments
Coding systems referenced:
ICD-9-CM, ICD-10-CM, CPT
Version:
1
Date:
June 2014
Authors:
Annie Kao; Bryony Aldous
Approver:
Mary Glover
Document type:
Clinical competency workbook
Subject:
Punch skin biopsy training and assessment
Target audience:
Registered children’s nurses (Band 6 or above)
Purpose:
Assessment of theoretical knowledge and practical competence in punch skin biopsy
Assessment requirements:
Completion of workbook; observation of two procedures; supervised performance of four procedures; competency sign-off
Related policies:
Medication Administration Policy (2012); Consent Policy (2013); Patient Group Directions Policy (2013); Hand Hygiene (2014); Disposal of Used Sharps (2014); Management of Severe Local Anaesthetic Toxicity (2010)
Procedure scope:
Punch skin biopsy only
Clinical setting:
Trust clinical practice
Year:
Not specified
Region / City:
Not specified
Topic:
Medical procedure, prostate biopsy
Document Type:
Consent form
Author:
Not specified
Target Audience:
Patients undergoing prostate biopsy
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Context:
A medical consent form outlining the risks, benefits, and procedure of transrectal ultrasound and prostate biopsy.
Year:
2020
Region / city:
Australia
Subject:
Health / Medical Services
Document type:
Factsheet
Organization / institution:
Medicare
Author:
MBS Review Taskforce
Target audience:
Healthcare providers, patients, medical professionals
Effective period:
From 1 May 2020
Approval date:
16 April 2020
Modification date:
N/A
Sample size:
10378 patients
Medical condition:
Prostate cancer
Subgroups:
Clinically significant prostate cancer (csPCa), Insignificant prostate cancer (Ins-PCa), All prostate cancer (PCa)
Variables analyzed:
Age, PSA level, Prostate volume (PV), PSA density (PSAD), PI-RADS score
Age categories:
<50; 50–60; 60–70; 70–80; ≥80 years
PSA categories:
<10; 10–20; 20–50; 50–100; ≥100 ng/mL; Unknown
Prostate volume categories:
<30; 30–40; 40–60; ≥60 ml; Unknown
PSA density categories:
<0.1; 0.1–0.15; 0.15–0.2; ≥0.2; Unknown
Imaging classification system:
PI-RADS (Prostate Imaging-Reporting and Data System)
Data type:
Quantitative clinical characteristics with counts and percentages
Medical field:
Urology / Oncology
Document type:
Statistical table of clinical study data